CR1 — When the Brain's Waste-Clearance Crew Falls Short
Complement receptor 1 (CR1, also known as CD35) is a molecular garbage collector. It sits on the surface of red
blood cells, monocytes, and dendritic cells, binding to complement-tagged debris — including
amyloid-beta oligomers | the toxic protein fragments that accumulate in Alzheimer's disease
— and shuttling them to the liver and spleen for destruction. The rs6656401 variant in the CR1 gene was
identified in 2009 as one of the first genome-wide significant Alzheimer's risk loci beyond APOE, and it
remains among the most robustly replicated genetic risk factors for late-onset disease.
The Mechanism
CR1 mediates immune adherence | the process by which complement-opsonized particles are bound to
erythrocytes and carried out of circulation. When complement proteins C3b or C4b coat
amyloid-beta aggregates in the bloodstream or cerebrospinal fluid, CR1 on circulating red blood cells
acts as a capture receptor, escorting the tagged debris to the reticuloendothelial system.
The CLU gene (clusterin), identified in the same 2009 paper, performs a complementary amyloid-chaperoning role —
lending biological plausibility to both genes as amyloid-clearance machinery.
The rs6656401 A risk allele sits within an intron of CR1 and functions as a
regulatory variant | it alters CR1 expression or splicing rather than changing the amino acid sequence.
A 2023 study measuring plasma protein levels showed that the A allele is significantly associated with
increased soluble CR1 (sCR1) concentrations — suggesting the risk mechanism may involve a shift from
membrane-bound CR1 (the functional form on erythrocytes) to its soluble, shed isoform. Elevated sCR1 in
plasma is believed to act as a decoy receptor, competing with and potentially inhibiting the
erythrocyte-bound CR1 that performs physiological clearance.
The Evidence
Lambert et al. (2009) in Nature Genetics | first GWAS to identify CR1 as an AD risk locus beyond APOE
reported an odds ratio of 1.21 (95% CI 1.14–1.29, P=3.7×10⁻⁹) for the rs6656401 A allele in a combined
European dataset of over 9,000 individuals. The association was validated across five independent European
cohorts, establishing CR1 as a genuine LOAD susceptibility locus.
A 2015 meta-analysis of 85,939 samples (30,100 cases; 55,839 controls) across 24 studies | the largest
pooled analysis specifically of rs6656401 confirmed the association with
OR=1.18 (95% CI 1.15–1.22, P=1.82×10⁻²⁶) in combined populations, and OR=1.31 in East Asian samples —
a finding that highlights population-specific effect sizes likely driven by differences in genetic
background and LD patterns.
Liu et al. (2021), synthesizing 30 studies with over 68,000 participants | the most comprehensive
systematic review of CR1 variants in LOAD, confirmed OR=1.23 (95% CI 1.10–1.36)
overall and OR=1.26 in European populations specifically, with the A allele as the risk allele in
all models tested. The evidence level is strong: the association has been independently replicated
across populations and study designs, and a plausible biological mechanism has been characterised.
Clinical-guideline-level evidence (CPIC/DPWG) does not yet exist for CR1 because there are no
genotype-specific approved interventions.
Practical Implications
Unlike pharmacogenomic variants with direct drug-dose consequences, the CR1 rs6656401 variant
informs risk stratification and motivates a specific biological target: complement-mediated amyloid
clearance. For A-allele carriers, the actionable focus is on supporting the complement and immune
pathways that handle amyloid burden, and on early monitoring.
Erythrocyte CR1 density varies by a HindIII RFLP polymorphism | the CR1 high-density (H) and
low-density (L) allele determining copy number on red cells
independently of rs6656401, and the relationship between rs6656401, sCR1 levels, and erythrocyte CR1
density is an active area of research. What is clear is that the A allele shifts complement biology in a
direction associated with impaired amyloid clearance and increased disease risk.
The most actionable steps for A-allele carriers center on: (1) monitoring cognitive function early to
catch any changes before they become irreversible, (2) managing the modifiable complement-
and inflammation-activating factors (metabolic health, sleep quality, cardiovascular fitness) that
amplify amyloid accumulation, and (3) awareness that participation in prevention trials is
particularly valuable given the established, replicated risk.
Interactions
The most important interaction is with APOE genotype (rs429358 + rs7412). APOE ε4 affects amyloid-beta
production and aggregation via lipoprotein pathways, while CR1 affects its clearance via complement.
Carrying both CR1 risk alleles and APOE ε4 may represent compounding impairment of two independent
amyloid-handling systems — accumulation plus impaired removal.
BIN1 rs744373 and CLU rs11136000 also influence amyloid and tau biology through different mechanisms.
While no single study has formally quantified the combined effect of all four loci, polygenic risk
scores incorporating CR1, BIN1, CLU, and APOE together predict Alzheimer's risk substantially better
than any single variant alone, supporting the additive model that guides action in high-risk carriers.
All Genotypes
Non-risk genotype; complement-mediated amyloid clearance unaffected by this variant
You carry two copies of the G allele at rs6656401, which is the common protective genotype. Approximately 77% of people carry this genotype globally. Your CR1-mediated complement clearance is not impaired by this variant. Alzheimer's disease risk from this locus is at population baseline; other genetic factors (particularly APOE status) and lifestyle variables will be the main determinants of your dementia risk.
One copy of the CR1 risk allele; modestly increased Alzheimer's risk
You carry one copy of the A risk allele at rs6656401, a genotype found in roughly 21% of the population. This confers approximately 21% increased odds of developing late-onset Alzheimer's disease compared to the GG genotype (OR ~1.21 from the original GWAS; OR ~1.18 from the 85,939-sample meta-analysis). The effect operates through a complement-biology mechanism — the A allele is associated with increased soluble CR1 levels, which may compete with erythrocyte-bound CR1 and reduce efficiency of amyloid-beta immune adherence and clearance. The absolute lifetime risk increase from a single A allele is modest; this genotype is best considered alongside APOE status and other risk factors.
Two copies of the CR1 risk allele; meaningfully elevated Alzheimer's risk
You carry two copies of the A risk allele at rs6656401, a genotype found in approximately 1.5% of the population. Homozygous carriers have the highest CR1-associated Alzheimer's risk from this locus — the additive model predicts roughly 45–50% increased odds relative to GG carriers (two risk copies × ~1.21 per copy in the additive model), with some studies reporting OR values around 1.36–1.55 for AA homozygotes specifically. Plasma soluble CR1 levels are significantly elevated in A-allele carriers, suggesting pronounced displacement of complement function from membrane-bound erythrocyte CR1 to a less-effective soluble form. This genotype is clinically meaningful particularly when combined with APOE ε4 status and other Alzheimer's risk factors.